Leqvio Adolescent (12 to 17) Transition to Adult Care

Why Transition Planning Matters for Adolescents on Inclisiran

Adolescents with HeFH who begin inclisiran at age 12 carry a lifetime atherosclerotic burden that already exceeds that of unaffected peers by decades. An interrupted treatment course during the transition from pediatric to adult care is one of the most preventable causes of LDL-C rebound in this population. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol states that "for patients with primary severe hypercholesterolemia (LDL-C ≥190 mg/dL), the potential for ASCVD risk reduction clearly favors statin therapy and additional LDL-C lowering," a principle that extends directly to PCSK9-targeting siRNA agents like inclisiran. [1]

The Atherosclerotic Clock Starts Early

Autopsy and imaging studies have shown fatty streak formation in the aorta beginning in the first decade of life in individuals with untreated FH. The PDAY study documented coronary artery involvement as early as the teenage years in hypercholesterolemic subjects. [2] Every six-month injection cycle completed during adolescence contributes to cumulative LDL-C reduction that compounds over a lifetime. Skipping even one dose at the transition gap widens that window by a full 180 days.

What Makes Inclisiran Different From Statins at Transition

Statins require daily adherence. Inclisiran requires two injections per year after the loading phase. That low-touch schedule is an advantage during the chaotic late-adolescent years, but it creates a specific structural risk: the six-month gap between doses can mask a missed injection for months before the next LDL-C check reveals the drift. Pediatric cardiology teams who understand this pharmacokinetic profile need to communicate it explicitly to the receiving adult internist or lipidologist.

FDA Approval Status for Adolescents and What It Means at Transfer

The FDA approved inclisiran for patients aged 12 and older with HeFH in June 2024, expanding the indication from the original adult label granted in December 2021. [3] The pediatric dose is 284 mg subcutaneous injection, identical to the adult dose, removing any dose-adjustment step at the moment of transfer. Prescribers inheriting an adolescent patient do not need to recalculate dosing. They do need to verify the injection schedule date so the adult clinic does not inadvertently reset the clock.

Reading the Pediatric Trial Data

The ORION-16 trial enrolled patients aged 6 to 17 with HeFH or familial hypercholesterolemia related to LDLR, APOB, or PCSK9 mutations. At 150 days, inclisiran produced a time-averaged LDL-C reduction of 39.6% versus a 1.5% increase in the placebo arm (P<0.001), with an adverse-event profile consistent with the adult ORION studies. [4] The 12-to-17 subgroup showed reductions comparable to those seen in adult ORION-9 data, where LDL-C fell by a mean of 49.9% from baseline at Day 510 in patients with HeFH. [5]

What the Adult Prescriber Inherits

When an adolescent crosses into adult care, the receiving clinician inherits:

• A patient already at steady-state siRNA silencing of hepatic PCSK9
• A genetic diagnosis (confirmed or presumed) of HeFH
• A statin and/or ezetimibe background regimen that should not be disrupted
• An injection logbook showing exact administration dates

Requesting these four items before the first adult visit prevents duplication of diagnostic workup and protects continuity of the pharmacological effect.

Recommended Transition Timeline

Most pediatric cardiology and lipid programs recommend beginning formal transition preparation at age 16. The process is not an event. It is a 12-to-24-month structured handoff that gives the adolescent time to develop self-management skills before losing the scaffolding of pediatric care.

Ages 16 to 17: Preparation Phase

At age 16, the pediatric team should:

1. Identify an adult lipidologist, preventive cardiologist, or internist with FH experience within the patient's insurance network.
2. Confirm that inclisiran is on the adult formulary and begin prior-authorization documentation. Commercial payers often require a new PA when the patient ages off a pediatric policy.
3. Review genetic testing results. If a pathogenic or likely pathogenic LDLR, APOB, or PCSK9 variant has not been confirmed, order it now so the adult provider has molecular documentation. The FH Foundation maintains a patient registry that facilitates this. [6]
4. Introduce the concept of self-advocacy. The patient should be able to name their diagnosis, state their most recent LDL-C value, and describe their injection schedule without parental prompting.

The Transfer Visit: What Must Happen

The actual transfer visit with the adult provider should occur no later than three months before the 18th birthday in most health systems. During that visit, four clinical tasks are non-negotiable.

First, reconcile the injection log. The adult provider should confirm the date of the last injection and schedule the next one prospectively. Second, order a fasting lipid panel if one has not been drawn within the prior 90 days. Third, review the concomitant statin dose. The 2023 ESC position statement on FH management in children and adolescents recommends that background statin therapy should achieve at least a 50% LDL-C reduction from untreated baseline before PCSK9 inhibition is added; if inclisiran was added on a suboptimal statin backbone, the adult visit is the time to optimize it. [7] Fourth, document the family history update. Between ages 12 and 18, a first-degree relative may have experienced a premature cardiovascular event that reclassifies the patient's risk tier.

Ages 18 and Beyond: Adult Care Consolidation

Once the patient is fully in adult care, the injection schedule continues at Day 1 (of adult care enrollment), Day 90, then every six months. The adult provider should set a calendar reminder system, since many patients in this age group do not have the annual-visit habits of older adults. A brief telehealth check-in at month three of each injection cycle to review any side effects reduces dropout.

The HealthRX Four-Domain Transition Readiness Framework

Standard transition readiness tools like the TRxANSITION Scale assess self-management across general domains. For adolescents on inclisiran specifically, four domains carry the most clinical weight.

Domain 1: Pharmacological Literacy. Can the patient explain that inclisiran works by silencing the PCSK9 gene messenger RNA in the liver, preventing the liver from clearing LDL receptors prematurely? A simplified version: "It teaches your liver to keep its cholesterol doors open." This level of understanding predicts adherence better than generic medication knowledge scores.

Domain 2: Injection Site Competency. Inclisiran is administered subcutaneously in the abdomen, upper arm, or thigh. Patients who have observed their own injections in the clinic and know the correct technique are less anxious about the adult setting's potential for a different nursing workflow.

Domain 3: Insurance Navigation. The adolescent should have watched at least one prior-authorization renewal cycle with their family before age 18. Adult PA processes for inclisiran can take 30 to 60 days. A patient who understands this buffer avoids a lapse.

Domain 4: Cardiovascular Risk Awareness. The patient should know their Simon Broome or Dutch Lipid Clinic Network score, their most recent LDL-C, and the name of any family member who had a heart attack before age 55 (men) or 65 (women). This contextualizes why lifelong therapy matters.

Managing LDL-C Targets After Transfer

Adult LDL-C targets for HeFH differ by risk tier. The 2018 ACC/AHA guideline stratifies very-high-risk patients, defined as those with established ASCVD or two or more major risk-enhancing factors, to an LDL-C goal <70 mg/dL. High-risk patients without established disease are targeted to <100 mg/dL. [1] Most adolescents transitioning at age 18 have not yet developed overt ASCVD, placing them in the high-risk tier, but subclinical atherosclerosis detected by carotid intima-media thickness (CIMT) measurement may shift that classification.

Role of CIMT and Coronary Calcium at Transfer

The 2023 ESC position statement recommends CIMT measurement in adolescents with FH to detect subclinical disease. [7] A CIMT above the 75th percentile for age and sex in a patient who is otherwise high-risk functionally upgrades their therapeutic urgency. If the adult provider has not received CIMT data from the pediatric team, ordering it at the first adult visit is reasonable. Coronary artery calcium (CAC) scoring is generally deferred in patients <30 years old due to low yield and radiation exposure, but the 2021 ESC Guidelines on cardiovascular disease prevention note that a CAC score of zero does not rule out high residual risk in confirmed FH. [8]

Titrating Background Statin Therapy

Inclisiran's LDL-C lowering is additive to statin therapy. In ORION-9, patients on maximally tolerated statin who received inclisiran achieved 49.9% further LDL-C reduction. [5] If the transitioning patient is on rosuvastatin 10 mg and not at LDL-C goal despite inclisiran, the adult visit presents the opportunity to uptitrate to rosuvastatin 20 or 40 mg before adding ezetimibe. The sequence matters. Statin dose optimization first, then ezetimibe, then confirm inclisiran adherence before concluding that the regimen has failed.

Common Barriers at Transition and How to Address Them

Insurance Coverage Gaps

Adolescents transitioning off a parent's pediatric health plan face formulary disruption. Novartis, the manufacturer of Leqvio, offers a patient support program called Leqvio Support Solutions that can bridge coverage gaps during insurance transitions. [9] The pediatric team should initiate contact with this program at age 16, not at age 18 when coverage has already lapsed.

Provider Unfamiliarity With Pediatric Inclisiran Data

Many adult internists have not yet prescribed inclisiran to patients in their mid-to-late 20s, let alone inherited an 18-year-old already on it. The receiving provider may be unfamiliar with ORION-16 pediatric data or uncertain about whether a new loading dose is needed at transfer. The answer is no: if the injection schedule is maintained, no reloading is required. The transfer summary from the pediatric team should state this explicitly.

Psychosocial Factors in Late Adolescence

Patients aged 17 to 19 are at elevated risk for treatment disengagement across chronic conditions. A 2020 systematic review published in the Journal of Adolescent Health found that transition-age youth with chronic illness showed higher rates of appointment non-attendance and medication discontinuation compared with established adult patients. [10] Inclisiran's every-six-month schedule reduces daily burden, but it does not eliminate the need for deliberate follow-up systems. Setting calendar-based injection reminders and pairing injection appointments with annual physical exams increases completion rates.

Monitoring Schedule After Transfer to Adult Care

The following schedule represents a reasonable clinical approach for the first 24 months of adult care in a patient with HeFH on inclisiran plus background statin.

• Month 0 (transfer visit): Fasting lipid panel, LFTs, CK, blood pressure, weight, BMI, family history update, injection log reconciliation.
• Month 3 (post-transfer): Injection of inclisiran if due per schedule; brief telehealth visit to confirm tolerability.
• Month 6: Fasting lipid panel to confirm LDL-C at target; CIMT if not done in prior 18 months.
• Month 12: Full cardiovascular risk reassessment, fasting lipid panel, review of statin dose.
• Month 18 and 24: Repeat lipid panel with each injection visit; escalate therapy if LDL-C remains <70 mg/dL target is not met.

A 2021 Cochrane review of lipid-lowering therapy adherence interventions found that structured monitoring schedules with defined follow-up intervals significantly improved persistence compared with open-ended care models. [11]

Shared Decision-Making: Engaging the Adolescent as a Partner

The 2022 AHA Scientific Statement on pediatric cardiovascular risk reduction emphasizes that shared decision-making between clinicians, patients, and families improves long-term adherence to preventive therapies. [12] For adolescents transitioning to adult care, this means shifting the communication dynamic from parent-led to patient-led in a deliberate, staged way.

At age 16, the patient should begin attending at least part of each appointment independently of their parent or guardian. By age 17, they should be the primary communicator with the clinical team during visits. By the transfer visit, the adult provider should be addressing the patient directly, not the accompanying parent, except when family history information requires parental input.

The FH diagnosis carries psychological weight. Young adults who understand they have inherited a condition that can be managed, not cured, show better long-term engagement when they have a named provider they trust in the adult system. Introducing the adult lipidologist by name during a joint visit at age 17, if geography allows, reduces the perceived discontinuity of care.

Injection Technique and Administration Notes for Adult Providers

Inclisiran 284 mg is supplied as a single-dose prefilled syringe for subcutaneous injection. Injection sites are the abdomen (avoiding the 2-inch radius around the navel), the upper arm, or the thigh. Sites should be rotated. The drug should not be injected into skin that is bruised, red, or tattooed. [13]

The injection is typically administered by a healthcare provider in clinic, distinguishing it from the self-injected PCSK9 monoclonal antibodies evolocumab and alirocumab. This in-office requirement is a structural advantage for adherence (the patient does not need to remember to self-inject) and a potential barrier if the patient cannot attend a clinic appointment. Some health systems have implemented home nurse visit programs for inclisiran administration; adult providers unfamiliar with this option should contact Novartis Medical Affairs for program availability.